|Bid||5.88 x 2900|
|Ask||6.00 x 4000|
|Day's range||5.70 - 5.90|
|52-week range||4.97 - 10.88|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.